Corbus Pharmaceuticals Holdings, Inc. 8-K

What Happened Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an 8-K reporting that on May 13, 2026 the board appointed Dr. Brent Pfeiffenberger (age 48) as an independent director, expanding the board to seven members. The company also held its annual meeting on May 13, 2026 where stockholders approved an amendment to the 2024 Equity Compensation Plan to increase authorized shares by 3,000,000 to a total of 5,000,000. A press release announcing the director appointment was issued May 14, 2026.

Key Details

• Director appointment: Brent Pfeiffenberger appointed May 13, 2026; currently President & CEO of Century Therapeutics (since Dec 2023) and chairman (Aug 2025); former senior roles at Neogene Therapeutics and Bristol‑Myers Squibb. He is designated independent under Nasdaq rules.
• Director compensation: non-employee directors receive a $40,000 annual cash retainer (pro‑rated for 2026) plus annual equity awards; an initial equity award for Dr. Pfeiffenberger is expected but not yet finalized.
• Equity plan increase: 2024 Plan amended to add 3,000,000 shares (new total 5,000,000); stockholder vote approved the amendment (5,950,038 for; 4,099,773 against; 24,259 abstentions; 4,060,300 broker non‑votes).
• Other votes: EisnerAmper LLP was ratified as auditor (14,102,264 for); advisory say‑on‑pay approved (9,325,932 for); advisory vote frequency approved for every year (9,712,048 for).

Why It Matters A new independent director with commercial and biotech leadership experience could influence Corbus’s strategic and commercial planning. The approved increase in the equity compensation pool gives management more shares to grant for hiring, retention and incentives—useful for growth but potentially dilutive to existing shareholders. Strong ratification of the auditor and approval of annual say‑on‑pay indicate shareholder support for the company’s governance and executive compensation approach as presented at the meeting. The company also entered a standard indemnification agreement with the new director.